Login
Companies $CATX
$0.94 +$0.01 (1.32%) After hours
Perspective Therapeutics, Inc. logo

Perspective Therapeutics, Inc.

perspectivetherapeutics.com

What Do They Do?

Develops targeted alpha-radiation cancer drug candidates and matching imaging diagnostics for patients with neuroendocrine tumors, melanoma and other solid tumors.

How Do They Make Money?

Government grants support qualifying project work, with grant revenue tied to eligible expenses as they are incurred. Product buyers submit purchase orders, and product sales are counted when the products ship.

FY2025 revenue

Who Are Their Customers?

Product buyers submit purchase orders, which Perspective accepts before delivering the products specified in the orders.

Do Revenues Turn Into Profits?

No. It lost $103.1M in FY2025.

Operating income, FY2025
−12847% of revenue
▼ −25% (Loss) vs FY2024 (−$90.9M, −6251%)
Net income, FY2025
−11665% of revenue
▼ −30% (Loss) vs FY2024 (−$79.3M, −5452%)
Free cash flow, FY2025
−10773% of revenue
▼ −31% (Loss) vs FY2024 (−$72.7M, −5001%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −25% (Loss)
vs −$26M in Q3 FY2025

Shrinking. Revenue fell 91% in 4 years, from $10.1M in FY2021 to $884K in FY2025, about 46% a year.

From seeds to drug development The earlier business sold cesium-based brachytherapy seeds and related devices for cancer treatment. The latest report describes development of targeted alpha-radiation drug candidates and matching imaging diagnostics for several cancers.

Who Do They Compete With?

Competes with Bayer, Novartis, Bristol Myers Squibb, Eli Lilly, Sanofi, Lantheus, Telix Pharmaceuticals, Actinium Pharmaceuticals, RadioMedix, AdvanCell, Orano Med, Aktis Oncology, AstraZeneca, Convergent Therapeutics, Johnson & Johnson, ARTBIO, Abdera, ITM, Ipsen, and Pfizer

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support